

CaRe Day May 17, 2018











Content

- Who is the audience and what do you expect from this talk?
 with the mentimeter
 Two short presentations
 Maroeska
- Jochen
- "College tour" → You can ask questions

Radboudumo

Question 1

- What is your current function?A. PhD student

 - B. Post-doc / assistant professor
 - Associate professor
 - D. Full professor

Radboudumc

Question 2

- Do you have or are you aiming for your own (successful) research group?

 - A. Yes, I am already leading a research group
 B. Yes, I am aiming to have my own group in the near future
 C. No, I prefer to act as a researcher (staff scientist) within a group
 D. No, I will quit academia as soon as I have finished my PhD

Radboudumc

Question 3

Ideally, in 5 years time I would like to spend the majority of my (working) week in:

- Teaching Clinical work
- Research
- Business/management
- Other

Radboudumc



http://www.youtube.com/watch?feature=player_detailpage&v=YZyUIHtxo

Radboudume

Short CV

1991- 1996: Biomedical Sciences, Radboudumc 1996- 2000: PhD, Radbudumc

2000-2001: Postdoc in Nottingham, UK 2002-2011: Clinical epidemiologist, UMC Utrecht As from 1 April 2012: Professor Evidence-based surgery, Radboudumc

Vice-chair ZONMW VENI Committee

> 25 awarded grant proposals (VENI, TOP, VICI) > 250 scientific publications (Lancet, NEJM, BMJ, PlosMed) various prizes

Radboudumc





































































Tension between ambition and SI

Bart Klemeney

Institute for Health Sciences Radboudumc

Three daily life situations

House of Commons Debate:

Group 1: Argues yes Group 2: Argues no

Group 3: Judges




Radboudume


Situation 1

Collaboration with a partner that has goals / procedures I do not support



Radboudumc







A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer

Lambertus A Kiemeney^{1-3-44*}, Patrick Sulem^{6,44}, Soren Besenbacher⁴, Sita H Vermeulen¹, Asgeir Sigurdsson⁴, Gudmar Thorlefisson⁴, Daniel F Gudbjartsson⁴, Simon N Stacey⁴, Julius Gudmundsson⁴, Carlo Zanon⁴, Jelena Kostic⁴, Gishi Masson⁴, Hordis Bjaranon⁶, Stefan Plasson⁶, Osbar B Skarphedimson⁴, Jelena Kostic⁴, Gishi Masson⁶, Hordis Bjaranon⁶, Stefan Daraphedimson⁸, Sei Chung Sak⁴, Ananya Choudhury⁷, Faye Bilon⁸, Jenson Joseph Barret⁸, Carlon P Hurst⁸, Petra I de Verdier⁸, Sei Chung Sak⁴, Analya Choudhury⁷, Faye Bilon⁸, Jenson Barret⁸, Carlon P Hurst⁸, Petra I de Verdier⁸, Sei Chung Sak⁴, Analya Carlotta Saccroficle Shi, Marcello Gampagan⁷, Donatella Jardic⁷, Sinia Polidoro ^{1,2,4}, Simonotta Guarren^{1,2,4}, Carlotta Saccroficle Shi, Marcello Gampagan⁷, Donatel Placidi⁷, Cecilla Artic⁷, Sinia Polidoro ^{1,2,4}, Simonotta Guarren^{1,2,4}, Carlotta Saccroficle Shi, Marcello Gampagan⁷, Donatel Placidi⁷, Cecilla Artic⁷, Sinia Polidoro ^{1,2,4}, Jana Cheng Regier^{1,2,4}, Manuel Sanchez^{2,4}, Hoger Districtich^{2,7}, Godmundur Geirsson^{2,5}, Signis Kinaliasson^{3,5}, Vidia Peturstotini^{2,5}, August Bong³, Thorget Thorgeirsson⁴, Sinia Polidoro ^{1,2,4}, Jana Polidoro ^{1,2,4}, Sinia P











Situation 1 Collaboration with a partner that has goals / procedures I do not support What should I do: quit my collaboration with this company?


Radboudumo


What did I do? - Embraced the collaboration - Expressed my concerns - Activities of company unrelated to our collaboration




Large biobanks / data sets N = 6700 population controls N = 2500 bladder cancer N = 7500 other cancers









Situation 2

Co-authorship on topics outside of your expertise

What should I do: reject co-authorship?



Radboudumo

What do I do?

- Accept co-authorship
- Someone has to be responsible for 'my' part
- Direct funding dependent on output
- Need financing for collaboration (postdoc)
- No co-authorship means data will not become available
- However, this becomes arbitrary with FAIR data

Radboudumc

Situation 3

Reviewing a competitive paper



Radboudumc

I am asked to review a paper for a high impact journal because of my specific expertise.

I notice from the abstract that the paper is from a competitor and describes a finding that I also found.

Unfortunately, I didn't find the time yet to submit my finding.

Radboudumc

Situation 3

Reviewing a competitive paper

What should I do: accept or decline request to review?




Radboudumc


What do I do?


- Accept request, but with disclosure to editor
- Try to be as objective as possible
- In case of recommendation to publish, offer journal possibility to publish back-to-back papers

Radboudumo




































How to cope with stress or pressure as researcher


Paula Meesters Graduate School Delft University of Technology






















Pressure: Expectations of Society


"You as scientists are the gatekeepers to Science. You must strive to engender a high level of trust. Science is at the origin of all technological progress, insofar as that is a key enabling cause of what we understand as social 'progress'. You should be the producer of truths and certainties."

S. Beernaerts: Head of Unit: DG Education and Culture; European Commission; Salamanca, Spain; March 2017














Psychologen TU Delft

How to cope with perfectionism and therefore stress?


1. Understand motivation, and fulfil human basic needs
2. Observe and change maladaptive perfectionistic beliefs
3. Develop your Autonomy as a researcher
4. Make stress your friend
















































NWO and ZonMw

- Merge between ZonMw and NWO into one legal entity will not happen
- ZonMw and NWO will continue to collaborate
 - Multi-disciplinary research projects
 - Chain from basic research, applied research, practical applications
- Same funding instruments and same strategic goals





But there is more: targets for transition of NWO

- More funding for innovative high-risk/highgain research
- More focus on collaboration and team science: across disciplines and with external stakeholders; more focus on societal impact
- More flexible to respond to new developments in science and society
- Coordinating role to set the national research agenda
- Transparant organisation
- Reduction of # funding instruments

IV-3 research: collaboration for excellence

- Facilitate collaboration between and across disciplines
- Team science
- Collaboration with other partners:
 - Top-sector (TS) policy: collaboration with private sector, especially SME.
 - Aim: more impact and more funding for research
 - National Research Agenda (NWA): coherence between TS, agenda's, ministeries, NWA research questions
 - International collaboration (Money follows
- Cooperation, Merian Fund, Big Science)
- Open Science (incl. Citizen Science)

IV: Ambitions NWO 2019-2022

- Nexus: connecting knowledge agenda's, research and society;
- People: perspectives for individual researchers;
- Research: collaboration for excellence;
- Infrastructure: accessible and sustainable research infrastructure;
- Knowledge use: effective use of knowledge design and co creation.





CaRe Award





Winner CaRe Award 2017

Ben Wijnen

Honorable mention: Caroline Kampshoff, Tessa Magnée, Annette Plouvier